Know Cancer

or
forgot password

Open Label Phase 2 Study of the Safety and Biological Activity of GCS-100 in Subjects With Chronic Lymphocytic Leukemia


Phase 2
18 Years
N/A
Not Enrolling
Both
Chronic Lymphocytic Leukemia

Thank you

Trial Information

Open Label Phase 2 Study of the Safety and Biological Activity of GCS-100 in Subjects With Chronic Lymphocytic Leukemia


The primary objective of this study is to evaluate the safety of GCS-100, and effect of
GCS-100 on markers of apoptosis in subjects with chronic lymphocytic leukemia. The
secondary objective of this study is to evaluate the effect of GCS-100 on peripheral blood
leukocyte count in subjects with chronic lymphocytic leukemia.


Inclusion Criteria:



Eligible subjects must meet all of the following criteria:

1. Subject is capable of understanding the purpose and risks of the study and is able to
provide written Informed Consent.

2. Subject is male or female, aged at least 18 years.

3. Subject has been diagnosed with chronic lymphocytic leukemia.

4. Subject has Stage II or higher, chronic lymphocytic leukemia that currently requires
therapy due to the severity of the disease symptoms and/or to the presence of
increasing anemia and/or increasing splenomegaly.

5. Subject has received 2 or fewer prior therapies for his/her chronic lymphocytic
leukemia.

6. Subject does not currently require blood transfusions.

7. Subject's peripheral blood leukocyte count is > 10,000 cells/mm3.

8. Subject's Karnofsky performance status is > 60%.

9. Subject's life expectancy is at least 3 months.

10. Female subjects of childbearing potential (i.e., women who have not been surgically
sterilized or have not been post-menopausal for at least 1 year), and male subjects
with partners of childbearing potential, must agree to use medically acceptable
methods of contraception throughout the entire study period.

11. Subject is willing and able to comply with the prescribed treatment protocol and
evaluations.

Exclusion Criteria:

Subjects will be ineligible for study participation if they meet any of the following
criteria:

1. Subject received biologic therapy and/or chemotherapy that may be active against
chronic lymphocytic leukemia within the 4 weeks prior to Study Day 1.

2. Subject is anticipated to require steroid therapy within the next 21 days.

3. Subject received an investigational (i.e., experimental) therapy within the 4 weeks
prior to Study Day 1.

4. Subject's clinical laboratory values meet any of the following criteria within the 7
days prior to Study Day 1:

- Platelet count < 25,000 cells/mm3

- Absolute neutrophil count < 500 cells/mm3

- Hemoglobin < 8.0 g/dL and with an autoimmune hemolytic component to the
subject's anemia

- AST and/or ALT > 2.5 X the upper limit of normal

- Total bilirubin > 1.5 X the upper limit of normal

- Serum creatinine > 2 mg/dL

5. Subject has a known history of human immunodeficiency virus (HIV), hepatitis B,
and/or hepatitis C infection.

6. Subject has a clinically relevant active infection and/or a serious co-morbid medical
condition, such as recent myocardial infarction, unstable angina,
difficult-to-control congestive heart failure, uncontrolled hypertension,
difficult-to-control cardiac arrhythmias, chronic obstructive or chronic restrictive
pulmonary disease, cirrhosis, inflammatory bowel disease.

7. Subject had major surgery within the 4 weeks prior to Study Day 1.

8. Subject had another malignancy within the 3 years prior to study entry, with the
exception of adequately treated basal cell or squamous cell skin cancer, in situ
cervical cancer, in situ breast cancer, in situ prostate cancer, or other cancer for
which the subject has been disease-free for at least 3 years.

9. If female, subject is pregnant or breast-feeding.

10. Subject has a concomitant disease or condition, including laboratory abnormalities,
which in the opinion of the Investigator could interfere with the conduct of the
study or could put the subject at unacceptable risk.

Type of Study:

Interventional

Study Design:

Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

To Evaluate the effect of GCS-100 on markers of apoptosis in subjects with chronic lymphocytic leukemia using physical examinations, vital signs, lab assessments, and adverse event reporting

Outcome Time Frame:

Up to 15 cycles X 21 days

Safety Issue:

Yes

Principal Investigator

David Smith, MD

Investigator Role:

Principal Investigator

Investigator Affiliation:

US Oncology

Authority:

United States: Food and Drug Administration

Study ID:

PR-CS008

NCT ID:

NCT00514696

Start Date:

February 2007

Completion Date:

April 2009

Related Keywords:

  • Chronic Lymphocytic Leukemia
  • Cancer
  • Leukemia
  • GCS-100
  • CLL
  • Leukemia
  • Leukemia, Lymphocytic, Chronic, B-Cell
  • Leukemia, Lymphoid

Name

Location

Virginia Oncology AssociatesNewport News, Virginia  23606
Rocky Mountain Cancer CentersThornton, Colorado  80260
Tyler Cancer CenterTyler, Texas  75702
Cancer Centers of FloridaOrlando, Florida  32806
Central Indiana Cancer CentersIndianapolis, Indiana  46227
Dayton Oncology & HematologyKettering, Ohio  45409
Northwest Cancer Specialists - Vancouver Cancer CenterVancouver, Washington  98684
Yakima Cancer CenterYakima, Washington  98902